Angiography Imaging System Research:CAGR of 5.82% during the forecast period

QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report "Angiography Imaging Systems- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Angiography Imaging Systems market, including market size, share, demand, industry development status, and forecasts for the next few years.

The global market for Angiography Imaging Systems was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/3997588/angiography-imaging-systems

Angiography Imaging System Market Summary

The term "Angiography Imaging Systems" in this article refers to fixed-position interventional X-ray angiography systems (DSA---Digital Subtraction Angiography Systems) used for catheter-based interventions and minimally invasive vascular treatments. Clinically, angiography/vascular imaging can be achieved through various pathways such as DSA, CTA, and MRA; however, from the perspective of OEM product definitions, hospital bidding project naming, and actual usage in end-hospital catheterization labs, the term "angiography equipment" typically refers specifically to medical angiography X-ray machines, i.e., digital subtraction angiography (DSA) systems. Therefore, this article's definition of Angiography Imaging Systems only covers fixed-position interventional X-ray angiography systems installed in cardiac catheterization labs, neurointerventional catheterization labs, interventional radiology departments, and hybrid operating rooms, used for real-time imaging and intraoperative guidance of coronary arteries, cerebral vessels, peripheral vessels, aorta, and related interventional treatments.

According to the new market research report "Global Angiography Imaging System Market Report 2026-2032", published by QYResearch, the global Angiography Imaging System market size is projected to grow from USD 5348 million in 2025 to USD 7869 million by 2032, at a CAGR of 5.82% during the forecast period.

Figure00001. Global Angiography Imaging System Top 11 Players Ranking and Market Share (Ranking is based on the revenue of 2026, continually updated)

Angiography Imaging System

Above data is based on report from QYResearch: Global Angiography Imaging System Market Report 2026-2032 (published in 2026). If you need the latest data, plaese contact QYResearch.

Globally, major manufacturers of angiography imaging systems include Philips, Siemens, GE HealthCare, Canon, and Shimadzu, with the top five manufacturers holding approximately 98% of the market share.

Currently, the core manufacturers worldwide are mainly located in Europe, the United States, and Japan.

Figure00002. Angiography Imaging System, Global Market Size, Split by Product Segment

Angiography Imaging System

Based on or includes research from QYResearch: Global Angiography Imaging System Market Report 2026-2032.

In terms of product type, floor-standing products are currently the most prominent segment, accounting for approximately 35.6% of the market share.

Figure00003. Angiography Imaging System, Global Market Size, Split by Application Segment

Angiography Imaging System

Based on or includes research from QYResearch: Global Angiography Imaging System Market Report 2026-2032.

In terms of product application, public hospitals are currently the primary source of demand, accounting for approximately 60% of the market share.

Figure00004. Angiography Imaging System, Global Market Size, Split by Region

Angiography Imaging System

Based on or includes research from QYResearch: Global Angiography Imaging System Market Report 2026-2032.

Supply Chain Analysis of Angiography Imaging Systems:

Upstream: Primarily includes key components such as X-ray tubes, high-voltage generators, flat-panel detectors, image chains and image processing boards, C-arms and gantry motion control, catheter beds, control software, displays, and contrast agent injectors. Among these, the X-ray tubes, detectors, and high-end control systems have the highest technological barriers.

Midstream: Complete system manufacturers handle hardware integration, software algorithms, system debugging, clinical validation, and registration, forming single-plane, dual-plane, and hybrid operating room solutions.

Downstream: Mainly large hospitals, specialized centers, and third-party imaging/interventional institutions, applied in cardiovascular, neurointerventional, peripheral vascular, and oncology interventional scenarios.

The entire industry chain also relies on supporting services such as installation and maintenance, parts replacement, software upgrades, clinical training, and financial leasing. The high-end market typically exhibits characteristics such as a high proportion of imported core components, integrated system and service, and strong after-sales support.

Market Drivers:

D1: The primary driver of global demand for angiography imaging systems is the expanding patient base for cardiovascular, cerebrovascular, and peripheral vascular diseases. The WHO states that cardiovascular disease remains the leading cause of death globally; simultaneously, the latest Global Burden of Disease study shows that cardiovascular disease remained the highest-burden secondary disease category globally in 2023, and related research projects that the number of people with cardiovascular disease, deaths, and daily adverse events (DALYs) will continue to increase significantly between 2025 and 2050. For hospitals, this means a continued increase in the demand for diagnosis, stratification, and interventional treatment of diseases such as coronary artery disease, stroke, peripheral artery disease (PAD), and aneurysms. These scenarios heavily rely on angiography systems for real-time imaging, catheter navigation, and intraoperative assessment; therefore, disease trends directly constitute the core support for long-term market growth.

D2: Aging is becoming a medium- to long-term structural driver for the angiography equipment market. OECD data shows that the proportion of the population aged 65 and over in OECD countries is projected to rise from 18.5% in 2023 to 26.4% in 2050, with a significant increase in the proportion of people aged 80 and over. The elderly population typically has more comorbidities such as atherosclerosis, arrhythmia, valvular disease, diabetes-related vascular complications, and chronic kidney disease, making them more reliant on coronary angiography, peripheral vascular intervention, neurointerventional, and postoperative follow-up. Simultaneously, elderly patients often require more frequent hospitalizations and multidisciplinary collaborative treatment, further increasing the utilization of catheterization labs and hybrid operating rooms. Therefore, an aging population not only expands the patient pool but also increases hospitals' demand for high-throughput, low-dose, and more efficient angiography systems.

D3: In recent years, medical services have been continuously shifting from open surgery to minimally invasive, percutaneous, and image-guided treatments, significantly increasing the importance of angiography systems. CIRSE clearly states that interventional radiology is a specialty that relies on image guidance to perform minimally invasive treatments, and with the widespread availability of high-quality imaging equipment, the available treatment options are constantly increasing. Related market research also shows that the global interventional radiology market will continue to grow between 2024 and 2035, reflecting hospitals' continued investment in building interventional treatment capabilities. For angiography systems, this means their role has gradually shifted from a simple diagnostic device to an interventional treatment platform, widely serving scenarios such as coronary intervention, tumor embolization, peripheral revascularization, aortic disease treatment, and neurointerventional. The increase in minimally invasive treatments will simultaneously drive demand for new installations, replacement of older equipment, and the construction of hybrid catheterization labs.

D4: Technological advancements are another key factor driving market growth. Current angiography systems are no longer limited to 2D fluoroscopy, but are increasingly integrating flat-panel detectors, 3D CBCT, automatic motion correction, dose management, navigation planning, and AI image chains. For example, Siemens Healthineers' next-generation platform, released in 2026, emphasizes improving image quality and interventional procedure accuracy at the same dose through automatic motion correction of 3D CBCT data, instrument navigation, and AI imaging chains. Technological upgrades enhance the ability to handle complex cases, improve workflow efficiency and physician experience, making hospitals more willing to replace existing equipment. Simultaneously, FDA regulations classify and regulate angiography X-ray and fluoroscopy systems, driving manufacturers to continuously iterate around safety, image quality, and standards compliance, thus creating a replacement-driven market.

Market Restraint:

R1: Angiography Imaging Systems are high-value, large-scale imaging devices. Beyond the main unit purchase, ongoing investments are involved, including catheterization lab renovations, shielding engineering, power and cooling systems, information system integration, maintenance services, detector and X-ray tube replacements, consumables management, and operator training. Therefore, the true cost of ownership far exceeds the one-time purchase price. For public hospitals with limited budgets, small and medium-sized medical institutions, and hospitals in emerging markets, even with clinical needs, procurement decisions are often delayed due to stringent capital expenditure approvals, rising financing costs, and long payback periods. The OECD has also consistently emphasized the significant impact of fiscal sustainability and budget constraints on capital investment in healthcare systems in recent years, meaning hospitals are becoming more cautious about upgrading large equipment. Consequently, market demand does not always translate into immediate deployment, especially in the areas of high-end two-way flat panel displays, hybrid operating rooms, and high-configuration interventional platforms, where this limitation is even more pronounced.

R2: Angiography imaging systems are highly complex and require stringent management of risks. Manufacturers must complete rigorous registration, testing, clinical validation, and quality system establishment before entering the market. In the United States, related products are subject to FDA regulations and performance standards for fluoroscopy/angiography X-ray systems. In Europe, the MDR framework significantly increases requirements for clinical evidence, post-market surveillance, and traceability. Simultaneously, devices must meet multi-dimensional compliance requirements, including radiation safety, dose control, electrical safety, software reliability, cybersecurity, and interoperability. For new entrants, this not only increases R&D and registration costs but also extends the product commercialization cycle; for existing companies, it means continuous investment in regulatory maintenance and upgrades. Therefore, while strict regulation helps improve industry quality, from a market expansion perspective, it may inhibit the entry of some small and medium-sized manufacturers and slow down the pace of new product launches.

R3: Angiography Imaging Systems, primarily based on X-ray fluoroscopy and contrast imaging, inherently face clinical limitations due to radiation exposure and contrast agent use. The FDA has explicitly stated that fluoroscopy, especially complex interventional procedures, can result in relatively high radiation doses, with the risk increasing with longer procedures and more complex cases. This forces hospitals to more rigorously balance clinical benefits with radiation exposure when performing related examinations and treatments and has driven some indications to be diverted to alternative methods such as CTA, MRA, and ultrasound. On the other hand, when contrast-enhanced examinations are involved, patient renal insufficiency, allergic reactions, and the safety management of gadolinium contrast agents must also be considered. The latest ESUR guidelines still emphasize the need for caution in the use of contrast agents in individuals with low eGFR. These risks will not necessarily hinder market development, but they will inhibit examination volume and equipment utilization in specific populations, for specific indications, and in some primary care facilities.

R4: Angiography systems are not standardized devices that can be "installed and used efficiently immediately." Their value realization highly depends on the coordination of interventional radiology, interventional cardiology, and neurointerventional teams, as well as anesthesia and nursing care, and the application support from equipment engineers and manufacturers. Many regions, especially small and medium-sized hospitals, grassroots markets, and non-core cities, still face problems such as a shortage of interventional specialists, a shortage of catheterization lab nurses and technicians, long training cycles, and heavy scheduling pressures. SIR's public materials in recent years have repeatedly mentioned that hospital closures, staff burnout, and labor shortages have put widespread pressure on interventional radiology departments; the OECD has also pointed out that healthcare workforce shortages have become a systemic challenge faced by many countries. Against this backdrop, even if a hospital completes the installation, it may be unable to quickly increase surgical volume and system uptime due to a lack of experienced teams, thus affecting the expected return on investment and, in turn, inhibiting subsequent expansion and replacement needs.

Trends Analysis:

T1: One of the most prominent trends in current angiography imaging systems is the evolution of AI and advanced imaging chains from localized functions to crucial components of overall platform competitiveness. Traditional angiography systems primarily compete with hardware parameters, detector performance, and basic image quality. However, new platforms released by manufacturers in the last two years have clearly shifted towards integrated solutions combining "AI + workflow + image optimization." For example, Siemens Healthineers' next-generation Artis's platform, released in 2026, emphasizes capabilities such as the Optiq AI imaging chain, 3D CBCT automatic motion correction, precise path planning, and instrument navigation, reflecting a shift in industry competition from simple hardware upgrades to software-driven intraoperative decision support and complex interventional assistance. Meanwhile, academic reviews also indicate that AI-driven ROI radiation control and image enhancement are becoming new directions for interventional imaging equipment. Overall, the value of future angiography systems will no longer be merely "visible," but rather "clearer vision, more efficient operation, and more intelligent dose control," which will drive AI to become a standard feature in high-end and mid-to-high-end products.

T2: As interventional procedures become more complex and procedures take longer, the industry's focus on radiation exposure and patient/caregiver safety has significantly increased, driving the continuous development of angiography systems towards lower doses and more refined management. The FDA has long maintained regulations and guidelines for fluoroscopy devices, and the industry is increasingly emphasizing dose optimization, standardized operating procedures, and training systems. A 2026 multidisciplinary blue belt expert recommendation published in JVIR further proposed establishing structured dose management processes and promoting more unified safety standards across different specialties. This means that future angiography systems will not only need to provide higher image quality but also achieve stable imaging at the same or lower doses, improving compliance and clinical acceptance through dose monitoring, preset protocols, automatic optimization, and safety alerts. For hospital procurement, low-dose capability gradually shifting from a "bonus" to a core evaluation indicator, especially in neurointerventional settings, pediatric cases, and high-frequency surgical centers, where this trend will become even more pronounced.

T3: From a market perspective, angiography systems are showing a clear stratification trend: on the one hand, large tertiary hospitals and highly complex centers continue to pursue high-end bidirectional flat panel displays, 3D navigation, AI image chains, and hybrid operating room solutions; on the other hand, more regional hospitals and emerging markets tend to choose systems that are more cost-effective, have more flexible floor space, and simpler procedures. Recent FDA 510(k) approval information and manufacturer activity show that, in addition to leading giants continuously launching high-end platforms, multi-functional R/F platforms targeting efficiency improvements, simplified operation, and reduced radiation are also entering the market, indicating that "high-end upgrades" and "mid-range popularization" are happening simultaneously. For manufacturers, this means that future competition will rely more heavily on stratified product portfolios and regional strategies: emphasizing intelligence, 3D capabilities, and complex interventional capabilities in mature markets, and emphasizing installation costs, usage efficiency, and after-sales accessibility in price-sensitive markets. This trend will drive the industry to form a clearer product structure of high-end flagships, mid-range mainstays, and regional alternatives.

The report provides a detailed analysis of the market size, growth potential, and key trends for each segment. Through detailed analysis, industry players can identify profit opportunities, develop strategies for specific customer segments, and allocate resources effectively.

The Angiography Imaging Systems market is segmented as below:
By Company
Philips Healthcare
Siemens Healthineers
Shimadzu Corporation
Canon Medical Systems
Omega Medical Imaging LLC
GE Healthcare
Boston Scientific Corporation
AngioDynamics
B. Braun Melsungen
Abbott
Medtron AG

Segment by Type
X-Ray Angiography
CT Angiography
MRI Angiography
MR-CT Angiography

Segment by Application
Cardiology
Oncology
Neurology
Peripheral and Vascular Intervention
Others

Each chapter of the report provides detailed information for readers to further understand the Angiography Imaging Systems market:

Chapter 1: Introduces the report scope of the Angiography Imaging Systems report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. (2021-2032)
Chapter 2: Detailed analysis of Angiography Imaging Systems manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. (2021-2026)
Chapter 3: Provides the analysis of various Angiography Imaging Systems market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. (2021-2032)
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.(2021-2032)
Chapter 5: Sales, revenue of Angiography Imaging Systems in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world..(2021-2032)
Chapter 6: Sales, revenue of Angiography Imaging Systems in country level. It provides sigmate data by Type, and by Application for each country/region.(2021-2032)
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. (2021-2026)
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Benefits of purchasing QYResearch report:

Competitive Analysis: QYResearch provides in-depth Angiography Imaging Systems competitive analysis, including information on key company profiles, new entrants, acquisitions, mergers, large market shear, opportunities, and challenges. These analyses provide clients with a comprehensive understanding of market conditions and competitive dynamics, enabling them to develop effective market strategies and maintain their competitive edge.

Industry Analysis: QYResearch provides Angiography Imaging Systems comprehensive industry data and trend analysis, including raw material analysis, market application analysis, product type analysis, market demand analysis, market supply analysis, downstream market analysis, and supply chain analysis.

and trend analysis. These analyses help clients understand the direction of industry development and make informed business decisions.

Market Size: QYResearch provides Angiography Imaging Systems market size analysis, including capacity, production, sales, production value, price, cost, and profit analysis. This data helps clients understand market size and development potential, and is an important reference for business development.

Other relevant reports of QYResearch:
Global Angiography Imaging Systems Market Outlook, In‐Depth Analysis & Forecast to 2031
Global Angiography Imaging Systems Market Research Report 2025
Global Angiography Imaging Systems Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
Email: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

About Us:
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 19 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 7 countries (include United States, Germany, Switzerland, Japan, Korea, China and India) and business partners in over 30 countries. We have provided industrial information services to more than 60,000 companies in over the world.

This release was published on openPR.